Your browser doesn't support javascript.
loading
Preliminary exploration on the role of clinical pharmacists in cancer pain pharmacotherapy.
Su, Ying-Jie; Yan, Yi-Dan; Wang, Wen-Juan; Xu, Tao; Gu, Zhi-Chun; Bai, Yong-Rui; Lin, Hou-Wen.
Afiliação
  • Su YJ; Department of Pharmacy, Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Yan YD; Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • Wang WJ; Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
  • Xu T; Department of Pharmacy, Ningbo First Hospital, Ningbo, China.
  • Gu ZC; Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. guzhichun213@163.com.
  • Bai YR; Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. baiyongrui@renji.com.
  • Lin HW; Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ann Palliat Med ; 9(5): 3070-3077, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32787363
ABSTRACT

BACKGROUND:

More than half of cancer patients affected by cancer experience pain of moderate-tosevere intensity. Therefore, facilitating appropriate and safe administration of analgesics is crucial to the comprehensive management of cancer patients. In this article, we assessed medication adherence, pain relief, drug related problems (DRPs) and analgesics adverse events (AEs) in cancer pain patients based on a model of clinical pharmacy services.

METHODS:

In this prospective, single-arm intervention study, cancer pain patients admitted to our institution were eligible. According to different adherence, heterogeneity of pain, and individual treatment strategy, clinical pharmacists (CPs) provided comprehensive pain assessment and medication education for patients, as well as provided consultation and recommendation for physicians. CPs' pharmacy services were assessed through medication adherence, numbers of DRPs, acceptance of recommendation, pain intensity (PI), daily interference and AEs.

RESULTS:

A total of 42 patients were enrolled between November, 2018 and November, 2019. Compared to baseline, patients' medication adherence evaluated with a medication adherence scale showed a significantly improvement at 14 and at 28 days after receiving CPs' interventions (8 score vs. 7 score at 14 days and at 28 days, P<0.01). During the 28-day follow-up, a total of 63 interventions were put forward according to 57 identified DRPs in 33 patients (78.6%), and approximately 95% (60/63) of the interventions were accepted by physicians. PI and daily interference significantly improved on the third day after the interventions of CPs, and the improvement continued until day 28 (P<0.01). AEs caused by opioids occurred in 19 patients (45.2%), and the most common one was constipation (14 patients, 33.3%).

CONCLUSIONS:

CPs' comprehensive interventions for cancer pain patients were efficacious in improving their medication adherence and pain relief, as well as reducing incidence of AEs. Therefore, this promising model should be replicated in other medical centers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Serviço de Farmácia Hospitalar / Dor do Câncer / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Serviço de Farmácia Hospitalar / Dor do Câncer / Neoplasias Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article